NORGESIC
LOE ApproachingNDAORALTABLET
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NORGESIC by Bausch + Lomb is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. First approved in 1964.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORGESIC is an oral tablet combination of orphenadrine citrate, aspirin, and caffeine approved in 1964 for muscle-related pain and spasticity. Orphenadrine is a centrally acting compound that blocks facilitatory functions of the reticular formation in the brain stem, with analgesic and anti-cholinergic properties. The exact mechanism of therapeutic action remains incompletely characterized.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting shrinking team and focus on cost management and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NORGESIC offers limited career advancement opportunities with zero linked job openings and a product in late lifecycle decline. Positions on this brand typically focus on managing market exit, optimizing manufacturing, and transitioning to generic formulations rather than growth initiatives.
Worked on NORGESIC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.